The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents
and who have failed fludarabine therapy.
The final section of the text is dedicated to molecular principles applied to specific toxicants and includes chapters on alkylating agents
and "mustards," oxidative stress in the erythrocyte, aromatic amines and related toxic compounds, polycyclic aromatic hydrocarbon carcinogens, and acetaminophen.
At one TRC member institution, the Massachusetts Institute of Technology (MIT), researchers are focusing their attention on the effects of simple and complex alkylating agents
, a class of DNA-damaging environmental toxins and toxicants that cause cell death, mutations, birth defects, and cancer.
are thought to work by producing free radicals in cancer cells and, in theory, antioxidants would interfere with this action.
Predisposition to treatment-related AML is primarily due to chemotherapy with alkylating agents
(nitrogen mustard, cyclophosphamide, procarbazine) or epipodophyllotoxins (etoposide, teniposide) (Table 3).
He and a team of researchers have developed a way to measure the ability of particular cancer cells to repair the damage done to DNA by a category of commonly utilized anti-cancer drugs that are known as alkylating agents
, including nitrosourea and cisplatinin.
Using these and other factors, the retrospective study of more than 9,000 patients provides strong statistical evidence that approximately half of the secondary bone cancers observed can be blamed on radiation therapy or on chemotherapeutic alkylating agents
such as the frequently prescribed cyclophosphamide.
In several malignancies alkylating agents
are still considered standard of care.
Radiotherapy and chemotherapy with alkylating agents
The classes of chemical compounds that cause cancer--including alkylating agents
, DNA-damaging agents, and toxicants that affect the cell cycle--vary in the mechanisms by which they cause the disease.
PredictMDx for Glioblastoma, MDxHealth's most advanced epigenetic assay is designed to identify newly diagnosed GBM patients most likely to benefit from treatment with alkylating agents
CHRONOS-2: A Phase III randomized, double-blind, placebo-controlled study of copanlisib in rituximab-refractory indolent NHL patients who have previously been treated with rituximab and alkylating agents